TuHURA Biosciences

HURA · NASDAQ

$1.76−$0.02 (−1.12%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.78

HURA analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 7 analysts

Average $8.20 (+366.0% upside)

Low: $6.26
Now: $1.76
High: $10.50

Upgrades and downgrades

The latest rating actions, newest first

HURA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Citizens	Aug 18, 2026	Maintains	Market Outperform	$9.00	14%
Citizens	Apr 27, 2026	Initiates	Market Outperform	$9.00	14%
HC Wainwright & Co.	Feb 3, 2026	Maintains	Buy	$10.00	41%
HC Wainwright & Co.	Jan 9, 2026	Maintains	Buy	$12.00 → $10.00	41%
Maxim Group	Nov 14, 2025	Maintains	Buy	$15.00 → $8.00	—

The case for and against

Updated Jun 23, 2026

Bull case

TuHURA Biosciences is currently valued at $636M using a DCF-based methodology, with a target price of $10 per share. Risks associated with this valuation include potential negative clinical results, delays in pipeline advancement, difficulty obtaining regulatory approvals, competition from other checkpoint inhibitors, and potential dilution in the medium-to-long term. However, as a phase 3 clinical stage company with a diverse portfolio of technologies, TuHURA Biosciences has the potential to overcome these risks and experience significant growth in the future.

Bear case

TuHURA Biosciences is currently facing a number of significant challenges, including a recent decline in stock price, which may be attributed to a lack of positive news and updates on their clinical trials, as well as the high costs associated with their research and development efforts. These challenges may hinder the company's ability to meet their upcoming value inflection points and could lead to delayed or disappointing results, making their stock a risky investment option.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.